Agenus (AGEN)
Develops investigational BOT+BAL antibodies for colorectal cancer and selected tumors.
$8.45
vs last close−0.25 (−2.92%)
Something off on this page? Send us feedback.
Next report
Nov 9, 26
in 47 days
EPS estimate
$0.02
Revenue estimate
$28.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$2.04−$1.03−$1.00$1.94$0.56$1.02−$0.01Pending
Estimate−$2.36−$1.61−$0.78$2.63−$1.27$2.10$0.05$0.02
Surprise+13.6%+36.0%−28.2%−26.2%+144.1%−51.4%−122.2%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$26.8M$24.1M$25.7M$30.2M$34.2M$33.7M$34.5MPending
Estimate$30.1M$22.1M$25.0M$28.1M$28.1M$129.5M$34.0M$28.2M
Surprise−10.8%+8.9%+2.8%+7.6%+21.7%−74.0%+1.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.88 | — | — |
| Sep 2027 | −$0.88 | — | — |
| Jun 2027 | −$0.88 | — | — |
| Mar 2027 | −$0.88 | — | — |
| Dec 2026 | −$0.28 | — | — |
| Nov 2026 | $0.02 | — | — |
| Aug 2026 | $0.05 | −$0.01 | −122.2% |
| May 2026 | $2.10 | $1.02 | −51.4% |
| Mar 2026 | −$1.27 | $0.56 | +144.1% |
| Nov 2025 | $2.63 | $1.94 | −26.2% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Mar 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.88 | — | — | $17.9M | — | — | — |
| Sep 2027 | −$0.88 | — | — | $17.9M | — | — | — |
| Jun 2027 | −$0.88 | — | — | $17.9M | — | — | — |
| Mar 2027 | −$0.88 | — | — | $17.9M | — | — | — |
| Dec 2026 | −$0.28 | — | — | $28.8M | — | — | — |
| Nov 9, 2026 | $0.02 | — | — | $28.2M | — | — | — |
| Aug 6, 2026 | $0.05 | −$0.01 | −122.2% | $34.0M | $34.5M | +1.5% | −3.7% |
| May 11, 2026 | $2.10 | $1.02 | −51.4% | $129.5M | $33.7M | −74.0% | −14.7% |
| Mar 16, 2026 | −$1.27 | $0.56 | +144.1% | $28.1M | $34.2M | +21.7% | +6.1% |
| Nov 10, 2025 | $2.63 | $1.94 | −26.2% | $28.1M | $30.2M | +7.6% | +5.8% |
| Aug 11, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 11, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 7, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 14, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 15, 2021 | |||||||
| Oct 29, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 10, 2019 | |||||||
| Mar 14, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 7, 2018 | |||||||
| Mar 15, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 4, 2017 | |||||||
| Mar 9, 2017 | |||||||
| Oct 27, 2016 | |||||||
| Jul 28, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Mar 3, 2016 | |||||||
| Oct 27, 2015 | |||||||
| Jul 23, 2015 |